alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 8095 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 8095

To amend the Internal Revenue Code of 1986 to extend the energy credit 
                 with respect to electrochromic glass.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             April 19, 2024

 Mr. Kelly of Mississippi (for himself, Mr. Horsford, and Mr. LaHood) 
 introduced the following bill; which was referred to the Committee on 
                             Ways and Means

_______________________________________________________________________

                                 A BILL

 
To amend the Internal Revenue Code of 1986 to extend the energy credit 
                 with respect to electrochromic glass.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. EXTENSION OF ENERGY CREDIT FOR ELECTROCHROMIC GLASS.

    (a) In General.--Section 48(a)(3)(A) of the Internal Revenue Code 
of 1986 is amended--
            (1) in clause (ii), by striking ``, or electrochromic glass 
        which uses electricity to change its light transmittance 
        properties in order to heat or cool a structure'',
            (2) in clause (x), by striking ``or''.
            (3) in clause (xi), by inserting ``or'' after the comma at 
        the end, and
            (4) by adding at the end the following new clause:
                            ``(xii) electrochromic glass which uses 
                        electricity to change its light transmittance 
                        properties in order to heat or cool a 
                        structure, but only with respect to property 
                        the construction of which begins before January 
                        1, 2033,''.
    (b) Conforming Amendment.--Section 48(a)(2)(A)(i)(III) of such Code 
is amended by striking ``paragraph (3)(A)(ii)'' and inserting ``clause 
(ii) or (xii) of paragraph (3)''.
    (c) Effective Date.--The amendments made by this section shall 
apply to property placed in service after the date of the enactment of 
this Act.
                                 <all>
```
§ 1.167(a)-6 Depreciation in special cases. ( a ) *Depreciation of patents or copyrights.* The cost or other basis of a patent or copyright shall be depreciated over its remaining useful life. Its cost to the patentee includes the various Government fees, cost of drawings, models, attorneys' fees, and similar expenditures. For rules applicable to research and experimental expenditures, see sections 174 and 1016 and the regulations thereunder. If a patent or copyright becomes valueless in any year before its expiration the unrecovered cost or other basis may be deducted in that year. See § 1.167(a)-14(c)(4) for depreciation of a separately acquired interest in a patent or copyright described in section 167(f)(2) acquired after January 25, 2000. See § 1.197-2 for amortization of interests in patents and copyrights that constitute amortizable section 197 intangibles.
( b ) *Depreciation in case of farmers.* A reasonable allowance for depreciation may be claimed on farm buildings (except a dwelling occupied by the owner), farm machinery, and other physical property but not including land. Livestock acquired for work, breeding, or dairy purposes may be depreciated unless included in an inventory used to determine profits in accordance with section 61 and the regulations thereunder. Such depreciation should be determined with reference to the cost or other basis, salvage value, and the estimated useful life of the livestock. See also section 162 and the regulations thereunder relating to trade or business expenses, section 165 and the regulations thereunder relating to losses of farmers, and section 175 and the regulations thereunder relating to soil or water conservation expenditures.
[T.D. 6500, 25 FR 11402, Nov. 26, 1960; 25 FR 14021, Dec. 21, 1960, as amended by T.D. 8867, 65 FR 3825, Jan. 25, 2000]
III

103D CONGRESS

1ST SESSION S. RES. 1

Informing the President of the United States that a quorum of each House

is assembled.

IN THE SENATE OF THE UNITED STATES

JANUARY 5, 1993

Mr. MITCHELL submitted the following resolution; which was considered and

agreed to

RESOLUTION

Informing the President of the United States that a quorum

of each House is assembled.

1 Resolved, That a committee consisting of two Sen2 ators be appointed to join such committee as may be ap3 pointed by the House of Representatives to wait upon the

4 President of the United States and inform him that a

5 quorum of each House is assembled and that the Congress

6 is ready to receive any communication he may be pleased

7 to make.

Æ
# C_2014431EN.01002802.xml

| 1.12.2014 | EN | Official Journal of the European Union | C 431/28 |
| --- | --- | --- | --- |

1.12.2014

EN

Official Journal of the European Union

C 431/28

---

Action brought on 4 July 2014 — Sweden v Commission

(Case T-521/14)

(2014/C 431/50)

Language of the case: Swedish

Parties

Parties

Applicant: Kingdom of Sweden (represented by: A. Falk and K. Sparrman, acting as Agents)

Applicant:

Defendant: European Commission

Defendant:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | Declare that the European Commission, by failing to adopt delegated acts to specify scientific criteria for the determination of endocrine-disrupting properties, has infringed Article 5(3) of Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products; |
| --- | --- |

—

Declare that the European Commission, by failing to adopt delegated acts to specify scientific criteria for the determination of endocrine-disrupting properties, has infringed Article 5(3) of Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products;

| — | Order the Commission to pay the costs of the action. |
| --- | --- |

—

Order the Commission to pay the costs of the action.

Pleas in law and main arguments

Pleas in law and main arguments

Under Article 5(3) of the Biocides Regulation (1), the Commission is to adopt delegated acts to specify scientific criteria for the determination of endocrine-disrupting properties by 13 December 2013 at the latest. The applicant submits that, by failing to adopt such delegated acts, the Commission has failed to take measures which it is obliged by law to take. The applicant has requested the Commission to adopt delegated acts in accordance with Article 5(3) of the Biocides Regulation, but in the Commission’s reply, in the view of the applicant, no position was defined as regards that request within the meaning of the second paragraph of Article 265 TFEU. The applicant claims that, in addition, as at the time of the application, the Commission has not adopted any measures to end the alleged failure to act. In the view of the applicant, the Commission has a basis for specifying scientific criteria for the determination of endocrine-disrupting properties and an application of those criteria which, under the second and third subparagraphs of Article 5(3) of the Biocides Regulation, are to apply until the Commission has adopted delegated acts containing criteria for endocrine-disrupting substances.

1

---

(1)  Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (OJ 2012 L 167, p. 1).

1

---
exv10w28



 





EXHIBIT
10.28









Director Compensation Summary



(to be effective as of the May 2007 Annual Meeting of the Board of Directors)

 




 

 










     Directors who also are employees of Quanta or any of its subsidiaries do not
receive additional compensation for serving as directors. Each non-employee director
receives a fee for attendance at each meeting of the Board of Directors or any
committee according to the following schedule: $2,000 for attendance at a board
meeting in person; $1,000 for attendance at a board meeting by telephone; $1,000 for
attendance at a committee meeting in person; and $500 for attendance at a committee
meeting by telephone. Upon initial appointment to the Board of Directors other than
at an annual meeting of stockholders, for the period from the appointment through
the end of the director service year during which the appointment is made, each such
initially appointed non-employee director receives a pro rata portion of both (i) an
annual cash retainer payment of $30,000 and (ii) an annual award of shares of
restricted Common Stock having a value of $75,000. Upon initial election to the
Board of Directors at an annual meeting of stockholders, each such initially elected
non-employee director receives an annual cash retainer payment of $30,000 and an
annual award of shares of restricted Common Stock having a value of $120,000. At
every annual meeting of stockholders at which a non-employee director is re-elected
or remains a director, each such re-elected or remaining non-employee director
receives an annual cash retainer payment of $30,000 and an annual award of shares of
restricted Common Stock having a value of $75,000. In addition, at every annual
meeting of the Board of Directors, the chairman of the Audit Committee receives an
annual cash retainer payment of $10,000, the chairman of the Compensation Committee
receives an annual cash retainer payment of $5,000 and the chairman of the
Governance and Nominating Committee receive an annual cash retainer payment of
$4,000. Unless the director’s service is interrupted, shares of restricted Common
Stock awarded to non-employee directors vest over three years in three equal annual
installments. Any unvested shares of restricted Common Stock will vest in full if
the non-employee director is not nominated for or elected to a new term or resigns
at our convenience. If the non-employee director voluntarily resigns or is asked to
resign, or is removed for cause prior to vesting, all unvested shares of restricted
Common Stock will be forfeited. Directors are reimbursed for reasonable
out-of-pocket expenses incurred in attending meetings of the Board of Directors or
the committees thereof, and for other expenses reasonably incurred in their capacity
as directors of Quanta.
<page> EXHIBIT 32.01

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report of Morgan Stanley
Principal Plus Fund L.P. (the ?Partnership?) on Form 10-Q for the
period ended June 30, 2006 filed with the Securities and Exchange
Commission on the date hereof (the ?Report?), I, Walter Davis,
President, Demeter Management Corporation, the general partner of
the Partnership, certify, pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that, to the best of my knowledge:
(1)	The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents,
in all material respects, the financial condition and
results of operations of the Partnership.









By:  	/s/ Walter Davis

Name:		    Walter Davis
Title:	    President

Date:		    August 14, 2006
QuickLinks
 -- Click here to rapidly navigate through this document

 
 

EXHIBIT 10.2    
  



Consent of Independent Auditors  


        We hereby consent to the incorporation by reference in the Registration Statement on Form F-3 (No. 33-63728) of Swedish
Export Credit Corporation of our report dated February 27, 2002 (except Note 1 (u) and Note 32 which are as of May 6, 2002 and the restatement within Note 1
(u) which is as of March 31, 2003 relating to the financial statements, which appear in this Annual Report on Form 20-F/A for the year ended December 31, 2001.
Our report refers to a restatement of U.S. GAAP net income for the year ended December 31, 2001. 



	 	 	 	KPMG
	 	 	 	 
	 	 	 	/s/  ANDERS LINÉR      
 Anders Linér

Authorized Public Accountant





April
7, 2003

Stockholm, Sweden 









QuickLinks



EXHIBIT 10.2
118TH CONGRESS 

2D SESSION H. R. 8089 

AN ACT 

To amend title XIX of the Social Security Act to require 

certain additional provider screening under the Medicaid 

program. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 
2 

•HR 8089 EH

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Medicare and Medicaid 

3 Fraud Prevention Act of 2024’’. 

4 SEC. 2. MEDICAID PROVIDER SCREENING REQUIREMENTS. 

5 Section 1902(kk)(1) of the Social Security Act (42 

6 U.S.C. 1396a(kk)(1)) is amended— 

7 (1) by striking ‘‘The State’’ and inserting: 

8 ‘‘(A) IN GENERAL.—The State’’; and 

9 (2) by adding at the end the following new sub10 paragraph: 

11 ‘‘(B) ADDITIONAL PROVIDER SCREEN12 ING.—Beginning January 1, 2027, as part of 

13 the enrollment (or reenrollment or revalidation 

14 of enrollment) of a provider or supplier under 

15 this title, and not less frequently than quarterly 

16 during the period that such provider or supplier 

17 is so enrolled, the State conducts a check of the 

18 Death Master File (as such term is defined in 

19 section 203(d) of the Bipartisan Budget Act of 
3 

•HR 8089 EH

1 2013) to determine whether such provider or 

2 supplier is deceased.’’. 

Passed the House of Representatives September 17, 

2024. 

Attest: 

Clerk. 
118TH CONGRESS 

2D SESSION H. R. 8089 

AN ACT 

To amend title XIX of the Social Security Act to 

under the Medicaid program. require certain additional provider screening
# C_2014282EN.01005301.xml

| 25.8.2014 | EN | Official Journal of the European Union | C 282/53 |
| --- | --- | --- | --- |

25.8.2014

EN

Official Journal of the European Union

C 282/53

---

Action brought on 2 July 2014 — Derivados del Flúor v Commission

(Case T-500/14)

2014/C 282/69

Language of the case: Spanish

Parties

Parties

Applicant: Derivados del Flúor, SA (Bilbao, Spain) (represented by: J. De Juan Casadevall, lawyer)

Applicant:

Defendant: European Commission

Defendant:

Form of order sought

Form of order sought

The applicant claims that the General Court should:

| — | annul the contested decision; |
| --- | --- |

—

annul the contested decision;

| — | in the alternative, if the ‘Spanish Tax Lease System’ (STLS) is held to be unlawful State aid, order recovery only until the date of publication in the Official Journal of the European Union of the decision initiating the formal investigation, namely, 21 September 2011; and |
| --- | --- |

—

in the alternative, if the ‘Spanish Tax Lease System’ (STLS) is held to be unlawful State aid, order recovery only until the date of publication in the Official Journal of the European Union of the decision initiating the formal investigation, namely, 21 September 2011; and

Official Journal of the European Union

| — | order the Commission to pay the costs. |
| --- | --- |

—

order the Commission to pay the costs.

Pleas in law and main arguments

Pleas in law and main arguments

By the present action, the applicant contests Commission Decision C (2013) 4426 final of 17 July 2013 on the tax regime applicable to certain finance lease agreements, also known as the Spanish Tax Lease System (State Aid SA.21233 C/2011 (ex NN/2011, ex CP 137/2006))

The pleas in law and main arguments are similar to those raised in Case T-401/14 Duro Felguera v Commission and Case T-700/13 Bankia v Commission.

Duro Felguera

Commission

Bankia

Commission

The applicant alleges, in particular: incorrect application in the present case of Articles 17, 18 and 19 of Council Regulation (EC) No 659/1999 of 22 March 1999 laying down detailed rules for the application of Article 108 TFEU; inexistence of a competitive tax advantage; incorrect identification of the beneficiary of the State aid; compatibility of the State aid with the interior market; misuse of powers by the Commission; and breach of the principles of equal treatment and the protection of legitimate expectations.

---
Editorial Note on Part 892
Editorial Note: Nomenclature changes to part 892 appear at 73 FR 35341, June 23, 2008.

§ 892.1570 Diagnostic ultrasonic transducer. ( a ) *Identification.* A diagnostic ultrasonic transducer is a device made of a piezoelectric material that converts electrical signals into acoustic signals and acoustic signals into electrical signals and intended for use in diagnostic ultrasonic medical devices. Accessories of this generic type of device may include transmission media for acoustically coupling the transducer to the body surface, such as acoustic gel, paste, or a flexible fluid container.
( b ) *Classification.* Class II.
Editorial Note on Part 890
Editorial Note: Nomenclature changes to part 890 appear at 73 FR 35341, June 23, 2008.

§ 890.5420 Electroencephalography (EEG)-driven upper extremity powered exerciser. ( a ) *Identification.* An EEG-driven upper extremity powered exerciser is a non-invasive prescription device intended for rehabilitation by driving movement or exercise of an impaired upper extremity in response to the detection of purpose oriented electrical activity produced by the patient's brain.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. Testing must capture any adverse events observed during clinical use and must demonstrate that the EEG signal can be translated into intended motion.
( 2 ) Software verification, validation, and hazard analysis must be performed.
( 3 ) Performance data must demonstrate the electromagnetic compatibility, electrical safety, battery safety, and wireless compatibility of the device.
( 4 ) The device components that contact the patient must be demonstrated to be biocompatible.
( 5 ) Performance data must validate the reprocessing instructions for the reusable components of the device.
( 6 ) Labeling must include: ( i ) Instructions on fitting the device to the patient;
( ii ) Information on how the device operates and the typical sensations experienced during treatment; and
( iii ) Reprocessing instructions.
[88 FR 983, Jan. 6, 2023]
```

[Federal Register Volume 74, Number 17 (Wednesday, January 28, 2009)]
[Notices]
[Page 4985]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-1822]

=======================================================================
-----------------------------------------------------------------------

THE NATIONAL FOUNDATION ON THE ARTS AND THE HUMANITIES

Meetings of Humanities Panel

AGENCY: The National Endowment for the Humanities.

ACTION: Notice of additional meeting.

-----------------------------------------------------------------------

SUMMARY: Pursuant to the provisions of the Federal Advisory Committee 
Act (Pub. L. 92-463, as amended), notice is hereby given that the 
following meeting of Humanities Panels will be held at the Old Post 
Office, 1100 Pennsylvania Avenue, NW., Washington, DC 20506.

FOR FURTHER INFORMATION CONTACT: Michael P. McDonald, Advisory 
Committee Management Officer, National Endowment for the Humanities, 
Washington, DC 20506; telephone (202) 606-8322. Hearing-impaired 
individuals are advised that information on this matter may be obtained 
by contacting the Endowment's TDD terminal on (202) 606-8282.

SUPPLEMENTARY INFORMATION: The proposed meeting is for the purpose of 
panel review, discussion, evaluation and recommendation on applications 
for financial assistance under the National Foundation on the Arts and 
the Humanities Act of 1965, as amended, including discussion of 
information given in confidence to the agency by the grant applicants. 
Because the proposed meeting will consider information that is likely 
to disclose trade secrets and commercial or financial information 
obtained from a person and privileged or confidential and/or 
information of a personal nature the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy, pursuant 
to authority granted me by the Chairman's Delegation of Authority to 
Close Advisory Committee meetings, dated July 19, 1993, I have 
determined that this meeting will be closed to the public pursuant to 
subsections (c)(4), and (6) of section 552b of Title 5, United States 
Code.
    1. Date: February 27, 2009.
    Time: 9 a.m. to 5 p.m.
    Room: 415.
    Program: This meeting will review applications for Humanities 
Initiatives (at Historically Black Colleges and Universities, High 
Hispanic Enrollment Institutions, and/or Tribal Colleges and 
Universities), submitted to the Division of Education Programs, at the 
January 15, 2009 deadline.

Michael P. McDonald,
Advisory Committee Management Officer.
[FR Doc. E9-1822 Filed 1-27-09; 8:45 am]
BILLING CODE 7536-01-P
```
§ 1.194-4 Time and manner of making election. ( a ) *In general.* Except as provided in paragraph (b) of this section, an election to amortize reforestation expenditures under section 194 shall be made by entering the amortization deduction claimed at the appropriate place on the taxpayer's income tax return for the year in which the expenditures were incurred, and by attaching a statement to such return. The statement should state the amounts of the expenditures, describe the nature of the expenditures, and give the date on which each was incurred. The statement should also state the type of timber being grown and the purpose for which it is being grown. A separate statement must be included for each property for which reforestation expenditures are being amortized under section 194. The election may only be made on a timely return (taking into account extensions of the time for filing) for the taxable year in which the amortizable expenditures were made.
( b ) *Special rule.* With respect to any return filed before March 15, 1984, on which a taxpayer was eligible to, but did not make an election under section 194, the election to amortize reforestation expenditures under section 194 may be made by a statement on, or attached to, the income tax return (or an amended return) for the taxable year, indicating that an election is being made under section 194 and setting forth the information required under paragraph (a) of this section. An election made under the provisions of this paragraph (b) must be made not later than, ( 1 ) The time prescribed by law (including extensions thereof) for filing the income tax return for the year in which the reforestation expenditures were made, or
( 2 ) March 15, 1984, whichever is later. Nothing in this paragraph shall be construed as extending the time specified in section 6511 within which a claim for credit or refund may be filed.
( c ) *Revocation.* An application for consent to revoke an election under section 194 shall be in writing and shall be addressed to the Commissioner of Internal Revenue, Washington, DC 20224. The application shall set forth the name and address of the taxpayer, state the taxable years for which the election was in effect, and state the reason for revoking the election. The application shall be signed by the taxpayer or a duly authorized representative of the taxpayer and shall be filed at least 90 days prior to the time prescribed by law (without regard to extensions thereof) for filing the income tax return for the first taxable year for which the election is to terminate. Ordinarily, the request for consent to revoke the election will not be granted if it appears from all the facts and circumstances that the only reason for the desired change is to obtain a tax advantage.
[T.D. 7927, 48 FR 55851, Dec. 16, 1983]